The synthesis, the antitumor activity, the SAR and, whenever described, the possible mode of action of 1,2,4-triazine derivatives, their N-oxides, N,. N'-dioxides as well as the benzo- and hetero-fused systems are reported. Herein are treated derivatives disclosed to literature from the beginning of this century up to 2016. Among the three possible triazine isomers, 1,2,4-triazines are the most studied ones and many derivatives having remarkable antitumor activity have been reported in the literature and also patented reaching advanced phases of clinical trials.
Cascioferro, S., Parrino, B., Spano', V., Carbone, A., Montalbano, A., Barraja, P., et al. (2017). An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 142, 328-375 [10.1016/j.ejmech.2017.08.009].
An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds
Cascioferro, Stella;Parrino, Barbara;Spanò, Virginia;Carbone, Anna;Montalbano, Alessandra;Barraja, Paola;Diana, Patrizia;Cirrincione, Girolamo
2017-12-15
Abstract
The synthesis, the antitumor activity, the SAR and, whenever described, the possible mode of action of 1,2,4-triazine derivatives, their N-oxides, N,. N'-dioxides as well as the benzo- and hetero-fused systems are reported. Herein are treated derivatives disclosed to literature from the beginning of this century up to 2016. Among the three possible triazine isomers, 1,2,4-triazines are the most studied ones and many derivatives having remarkable antitumor activity have been reported in the literature and also patented reaching advanced phases of clinical trials.File | Dimensione | Formato | |
---|---|---|---|
E. J. Med. Chem. 142 (2017) 328-375.pdf
Solo gestori archvio
Descrizione: Articolo principale
Tipologia:
Versione Editoriale
Dimensione
3.45 MB
Formato
Adobe PDF
|
3.45 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.